Apr 16, 2021
Immutep Receives A$1,155,055 R&D Tax Incentive
Apr 07, 2021
Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer
Apr 06, 2021
Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy
Mar 17, 2021
Immutep To Participate In A Fireside Chat At The Inaugural M Vest And Maxim Group Emerging Growth Virtual Conference
Mar 16, 2021
Immutep Enters Second Collaboration with MSD for a New Randomised Phase IIB Trial in Head and Neck Cancer
Mar 09, 2021
Immutep Secures Second United States Patent Grant For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
Mar 05, 2021
Immutep Expands Part B of TACTI-002 Study
Jan 26, 2021
Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study
Jan 21, 2021
Immutep Quarterly Activities Report
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
Jan 05, 2021
Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study
Dec 28, 2020
Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
